triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial Eli Lilly just announced striking 3 results retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% Lilly's triple agonist, retatrutide, successful

The higher the basal metabolic rate, the more calories the body burns every day, which is more conducive to maintaining weight stability

Natasha Yates wishes to thank Dr Terri-Lynne South a GP, dietician, and the chair of the Royal Australian College of General Practitioners specific interest group in obesity management for providing feedback and peer review on this article.

: 2 , , , , -1

Exendin-4 protects adipose-derived mesenchymal stem cells from apoptosis induced by hydrogen peroxide through the PI3K/Akt-Sfrp2 pathways

Take L-carnitine and L-carnosine, for instance: on the surface, they sound very similar but when you look closely, some critical differences make them stand apart